45 results about "Lymphocyte proliferation" patented technology

The invention discloses a dendrobium huoshanense polysaccharide nanoemulsion immunologic adjuvant and a preparation method thereof. The dendrobium huoshanense polysaccharide nanoemulsion immunologic adjuvant is prepared from the following raw materials in percentage by mass: 0.1%-2.0% of dendrobium huoshanense polysaccharide, 20%-30% of a surfactant, 5%-10% of a cosurfactant, 5%-10% of an oil phase and the balance of deionized water. The preparation method of the nano-emulsion is simple and easy to implement, equipment is easy to control, the cost is low, and the obtained nano-emulsion is small in droplet particle size, high in stability and capable of improving the spleen lymphocyte proliferation activity of immunocompromised mice. The nanoemulsion can significantly improve the immunomodulatory activity of dendrobium huoshanense polysaccharide, and has the potential of developing immunopotentiators, thereby promoting the development and utilization of traditional Chinese medicine resources and active components thereof.

The invention discloses preparation and application of porcine reproductive and respiratory syndrome virus circular RNA (Ribonucleic Acid) and a vaccine. The circular RNA encodes and expresses GP5 protein optimized by the porcine reproductive and respiratory syndrome virus and M protein optimized by the porcine reproductive and respiratory syndrome virus. The optimized circular RNA molecule is prepared into a vaccine to successfully induce a high-level neutralizing antibody in a pig body, so that the proportion of CD4 + IFN-gamma + and CD8 + IFN-gamma + cells in PBMC cells is remarkably increased, the lymphocyte proliferation activity after specific stimulation of a virus antigen is remarkably improved, and the protection of the porcine reproductive and respiratory syndrome virus is effectively realized. The invention provides a basis for preparing the RNA vaccine for preventing and / or treating the porcine reproductive and respiratory syndrome virus.

The invention discloses an application of Northeast tiger interleukin-15 in preparation of an antiviral drug. According to the invention, IL-2 family genes (IL-2, IL-4, IL-9, IL-15 and IL-21) and IL-13 genes of the northeast tiger are cloned and successfully expressed. Functional experiments show that all cytokines can promote lymphocyte proliferation, F81 cells are pretreated with IL-15 and then exposed to feline panleucopenia virus (FPV) derived from northeast tiger, and different exposure time is set for subsequent experimental research. The consistency of flow cytometry, protein expression analysis and ROS staining results shows that IL-15 can significantly weaken oxidative stress and apoptosis induced by FPV infection. In conclusion, the molecular and functional characteristics of the northeast tiger IL-2 cell factor family are clarified, and IL-15 is highlighted as a cell factor with a potential antiviral protection effect. The results provide technical means for cytokine-based immunological research and potential treatment strategy development to support health and protection of northeast tigers in the future.

This invention belongs to the field of plant extract technology, specifically relating to a plant extract composition for enhancing immunity. By weight, it is composed of the following raw materials: 3-5 parts Astragalus membranaceus extract, 2.5-4 parts Echinacea purpurea extract, and 1.5-3.5 parts Rhodiola rosea extract. This plant extract composition, through the scientific formulation of Astragalus membranaceus, Echinacea purpurea, and Rhodiola rosea, and an enzymatic extraction process, enhances the immunomodulatory effect. The combination of the three extracts increases the secretion of TNF-α and IL-6 by macrophages. Furthermore, the spleen lymphocyte stimulation index (SI) of the three extracts reaches 5.57, and the lymphocyte transformation rate increases from 191% to 457%. These results indicate that this plant extract composition effectively enhances the body's non-specific and cellular immune functions by activating macrophages and promoting T lymphocyte proliferation through multiple pathways, providing more comprehensive immune protection.

The invention belongs to the technical field of vaccine preparation, and particularly relates to a porcine PRRSV (porcine reproductive and respiratory syndrome virus) and PCV2 (porcine circovirus 2) recombinant adenovirus bivalent vaccine as well as a preparation method and application thereof. The porcine PRRSV and PCV2 recombinant adenovirus bivalent vaccine provided by the invention comprises a recombinant adenovirus 1 for expressing PRRSV GP5, M and PCV2 TBCap proteins and a recombinant adenovirus 2 for expressing PRRSV GP2, GP3, GP4 and N proteins. After a piglet is immunized by the vaccine, high-level PRRSV and PCV2 specific antibodies and neutralizing antibodies can be induced to be generated, and the lymphocyte proliferation activity of the piglet and the expression level of cell factors IFN-gamma / IL-2 / IL-4 are also remarkably improved, so that the prepared vaccine can stimulate a body to generate humoral immune response and cellular immune response. The invention provides a direction for prevention and control of the PRRSV and the PCV2.

The present application provides chimeric anti-CD27 antibody molecules and encoding nucleic acids and expression vectors thereof. The anti-CD27 antibody molecules of the present application can specifically bind to CD27 and have effects of stimulating lymphocyte proliferation, activating lymphocytes, etc.

The invention relates to a compound red date extract with an immune regulation function as well as a preparation method and application thereof. The composite red date extract is prepared by taking red dates, astragalus membranaceus, Chinese yam, poria cocos, sea-buckthorn and medlar as raw materials through extraction, concentration and drying, and can be prepared into health-care food with an immune regulation function. Experiments prove that the compound red date extract prepared by the invention can enhance lymphopoiesis, delayed allergy, antibody generation, macrophage phagocytosis and NK cell activity, comprehensively improve the immune function and meet the health-care function requirement of enhancing immunity. The immunomodulatory activity of the compound red date extract is researched for the first time, and the compound red date extract has the advantages of being simple in production process, prominent in health-care function, small in dosage, safe to use, capable of being produced on a large scale and the like, thereby having wide application prospects in the aspect of preparing medicines and health-care foods for improving immunity.

The present application provides a chimeric anti-CD27 antibody molecule composition and its application. The anti-CD27 antibody molecule of the present application can specifically bind to CD27 and has the effects of stimulating lymphocyte proliferation, activating lymphocytes, etc.

The invention discloses a crocodile blood composition for improving immunity and application. The composition provided by the invention comprises the following raw materials in parts by weight: 30-60 parts of crocodile plasma powder, 1-7 parts of liquorice, 5-10 parts of radix asparagi, 3-10 parts of schisandra chinensis, 4-10 parts of codonopsis pilosula, 8-15 parts of lucid ganoderma, 2-8 parts of American ginseng and 1-5 parts of vitamin C. The composition is rich in various active substances capable of improving immunity, and can improve the immunity of the crocodile blood, promote the release level of immunomodulatory factors TNF-alpha and IL-2, increase the total number of spleen and lymphocytes and the volume of white marrow and lymph node cortex of the spleen through the cooperation of specific Chinese herbal medicine components and bioactive components in the crocodile blood, and improve the immunity of the crocodile blood. The immunosuppression effect is reduced, and the lymphocyte proliferation capacity is remarkably improved. The composition provided by the invention is green and safe in raw materials, rich in nutrition, and capable of enhancing the effect of crocodile blood and enhancing the immunity of the organism.

The invention discloses a method for evaluating in-vitro lymphopoiesis inhibition of mesenchymal stem cells, and relates to the technical field of biological medicine, the method for evaluating in-vitro lymphopoiesis inhibition of mesenchymal stem cells comprises the following steps: S1, preparing an MSC cell suspension; s2, preparing a PBMC (peripheral blood mononuclear cell) suspension, namely preparing a commercialized mixed source PBMC with a built line; s3, MSC inoculation adherent culture is carried out; s4, carrying out CFSE dyeing and inoculation; s5, marking the PBMC proliferative cells by using the MSC: after culture is completed, adding a cell activity detection reagent, incubating in a dark place, detecting, and carrying out statistical analysis; according to the method, the sample size of the same batch of PBMCs is increased by adopting commercialized established-line mixed source PBMCs, so that the difference between batches is reduced; compared with a traditional evaluation method, the method provided by the invention can more comprehensively and reliably evaluate the in-vitro lymphocyte proliferation inhibition capability, so that a basis is provided for clinical application of mesenchymal stem cells.

The invention relates to the technical field of preparation of probiotic fermented beverages, in particular to a probiotic fermented fruit and vegetable beverage with functions of resisting fatigue and enhancing immunity. The hawthorn fruit beverage specifically comprises the following components in parts by mass: 60-80 parts of Zhongtian big hawthorn fruits, 10-20 parts of autumn pears, 11-15 parts of grapes, 9-15 parts of kiwi fruits, 6-10 parts of pomegranates, 3-5 parts of figs, 3-5 parts of beet roots, 3-5 parts of pumpkins, 1-2 parts of kale, 1-2 parts of honey and 2-3 parts of zymophyte. The beverage product provided by the invention can significantly prolong exhaustive swimming time, improve liver glycogen reserve, reduce serum urea nitrogen level after exercises, and effectively relieve physical fatigue; meanwhile, the food can comprehensively enhance the immune function of the organism, including improving the activity of phagocytes, promoting the proliferation of lymphocytes and enhancing humoral immune response, and provides a natural and healthy solution for resisting fatigue and enhancing the immunity function through daily diet for consumers.

The application discloses an immune regulation pharmaceutical effect analysis method based on a concentrated pill of psammochloa and astragalus, which comprises the following steps: raw material extraction, animal model construction, multi-dimensional detection and data statistics. The raw materials of psammochloa and astragalus are weighed according to a specific ratio, and then are prepared into extract by ethanol decoction and concentration. After the experimental animals are grouped and administered intragastrically, the individuals are screened by the four oxygen pyrimidine modeling. The immune organs are separated, weighed, and the index is calculated. The contents of various cytokines in serum and liver tissue are detected by the ELISA method. The tissue morphology, lymphocyte proliferation and protein expression are observed by HE staining, MTT method and immunofluorescence method. The expression of key signal pathway proteins is detected by electrophoresis and other steps after the total protein is extracted, and statistical analysis is carried out. The method is systematic and comprehensive, the result is accurate and reliable, and a scientific basis is provided for the immune regulation pharmaceutical effect evaluation of the concentrated pill.

This invention discloses a PRRSV NADC30 lineage vaccine, its preparation method, and its applications, belonging to the field of immunology technology. The recombinant chimpanzee adenovirus vector is obtained by introducing the encoding gene of GP35 fusion protein or M-GP5 fusion protein into an expression vector; wherein, the GP35 fusion protein is constructed by linking GP3 and GP5 proteins with a flexible linker peptide; the M-GP5 fusion protein is constructed by linking M and GP5 proteins with a flexible linker peptide. The PRRSV NADC30 lineage vaccine of this invention achieves protection against PRRSV infection by inducing antigen-specific antibodies, neutralizing antibodies, Th1-type cellular immune responses, and / or lymphocyte proliferation reactions. This invention provides a promising candidate antigen and a highly efficient vaccine platform for developing novel recombinant chimpanzee adenovirus vector vaccines against currently circulating NADC30-like strains.

The present application provides recombinant anti-CD27 antibody molecules, and encoding nucleic acids and expression vectors thereof. The anti-CD27 antibody molecules of the present application can specifically bind to CD27, and have effects of stimulating lymphocyte proliferation, activating lymphocytes, etc.

The present invention relates to use of β-glucan extracts in the immunopotentiation of an avian animal. Specifically, the present invention provides a kit, wherein the kit comprises (1) an immunopotentiator used for immunopotentiation of an avian animal, wherein the immunopotentiator comprises a β-glucan extract which is extracted from Saccharomyces cerevisiae cell wall; and (2) a virus vaccine. The present invention also provides use of a β-glucan extract which is extracted from Saccharomyces cerevisiae cell wall, in the preparation of a kit used for immunopotentiation of an avian animal and immunopotentiator. The present invention uses a β-glucan extract, which is extracted from Saccharomyces cerevisiae cell wall, for immunopotentiation of an avian animal, which can enhance lymphocyte proliferation responses and T cell responses of vaccinated animals; decrease the viral load; reduce the morbidity or mortality; produce antibodies in advance; and increase antibody production; and / or restrict the spread of the virus.

The invention discloses an immune effect evaluation method of a cysticercus cellulosae recombinant TPx protein vaccine, and belongs to the technical field of biological medicines. The vaccine takes recombinant thioredoxin peroxidase (TPx) from cysticercus cellulosae as an immunogen, and an adjuvant (such as a Freund's adjuvant) can be optionally supplemented to enhance the immune effect. A mouse is immunized through subcutaneous injection of the vaccine, it is proved that the vaccine can effectively induce an organism to generate humoral immune response and cellular immune response, specifically, the levels of serum IgG, IgG2a and IgG1 antibodies are remarkably increased, the proliferation capacity of splenic lymphocytes is enhanced, and the secretion levels of Th1 type cell factors (TNF-alpha and IL-12) and Th2 type cell factors (IL-13 and IL-10) are remarkably increased. The invention provides a new candidate vaccine for prevention of cysticercosis, and has important application value.

The invention relates to the technical field of plant polysaccharide extracts, in particular to a fructan polysaccharide substance derived from rhizoma atractylodis macrocephalae and application of the fructan polysaccharide substance in preparation of anti-aging drugs. According to the fructan polysaccharide substance AMP, the AMP is neutral fructan, a main chain is formed by alternating 1, 2-connected beta-D-fructofuranose, 2, 6-connected beta-D-Fuf and 1, 2, 6-connected beta-D-Fuf, and a side chain is selected from one or more of alpha-L-arabinofuranose, 1, 3-connected alpha-D-glucopyranose and beta-D-Fuf. The chemical structural characteristics and properties of AMP, including functional groups, monosaccharide composition, molecular weight, spatial conformation, crystallization characteristics and stability, are analyzed. The AMP activates a spleen GPR41 / GPR43 signal channel, promotes T / B lymphocyte proliferation and relieves the G1 phase retardation of a cell cycle by improving the generation of intestinal short-chain fatty acid, especially butyric acid, so that the imbalance of peripheral lymphocyte subpopulations is corrected, tissue aging and DNA damage markers are reduced, and the purposes of recovering immune homeostasis and delaying immune decline are achieved.

The present application belongs to the technical field of alternative immunomodulators, and particularly relates to a preparation method of a Passiflora edulis immunomodulator for pigs and application thereof, which comprises the following steps: inoculating activated gold flower fungus into a liquid culture medium to prepare seed liquid; pretreating Passiflora edulis fruits, cutting or crushing the Passiflora edulis fruits to prepare a fermentation substrate, and adding bran and / or corn powder as an auxiliary carbon source; sterilizing the fermentation substrate; inoculating the seed liquid to perform solid or liquid fermentation; in the fermentation process, the gold flower fungus secretes an enzyme system to destroy the cell wall of the Passiflora edulis, release and convert polysaccharides and flavonoid active ingredients; and drying and crushing to obtain the Passiflora edulis immunomodulator for pigs. The immunomodulator can be added into pig feed to significantly improve the spleen index, macrophage phagocytic activity, lymphocyte proliferation capacity and serum IgG level, reduce the diarrhea rate, and promote growth performance. The present application combines the gold flower fungus and the Passiflora edulis to prepare the immunomodulator for pigs, which can be used to replace antibiotics and promote healthy pig breeding.

This invention relates to the field of biomedical technology, and in particular to mesenchymal stem cells, their preparation methods, and applications. The method for preparing mesenchymal stem cells includes the following steps: culturing the mesenchymal stem cells under hypoxic conditions with an oxygen volume fraction of 2%–4%, and during the hypoxic culture, pre-activating the mesenchymal stem cells by contacting them with an induction system containing 1–3 ng / mL Oncostatin M, 1–10 ng / mL IL-1β, and 2–10 ng / mL HMGB1 for 6–24 hours. Mesenchymal stem cells treated by this method can significantly inhibit lymphocyte proliferation, reduce the proportion of pro-inflammatory T cell subsets such as Th1 and Th17, increase the proportion of Treg cells, and effectively reduce the level of the inflammatory factor TNF-α.

The present application provides anti-CD27 antibody compositions and uses thereof. The anti-CD27 antibodies of the present application are capable of specifically binding to CD27 and have effects of stimulating lymphocyte proliferation, activating lymphocytes, etc.

The invention belongs to the technical field of vaccines, and particularly relates to a self-assembled ferritin nanoparticle recombinant protein SFT as well as a preparation method and application thereof. The recombinant protein SFT is formed by self-assembly of a SpyCatcher 003-Fel protein and a SpyTag003-TB10.4 protein, and the SpyCatcher 003-Fel protein and the SpyTag003-TB10.4 protein are used as Compared with a monomer TB10.4, the tuberculosis vaccine prepared by utilizing the self-assembled ferritin nanoparticle recombinant protein SFT has the advantages that the lymphocyte proliferation level is obviously improved by subcutaneous immunization of the SFT under the condition that an adjuvant is not used, and the tuberculosis vaccine has the capability of inducing T cell activation and can stimulate various TB related cell factors. The results show that the SFT is obviously superior to the traditional recombinant protein and vaccine, the variety of novel tuberculosis candidate vaccines is widened, and a nanoparticle capture platform is provided for other tuberculosis antigens in the future.

This invention discloses the application of a thermostable antigen of Mycobacterium tuberculosis, belonging to the field of biomedical technology. This invention provides an application of the thermostable antigen of Mycobacterium tuberculosis (Mtb-HAg). Immunization of mice with Mtb-HAg alone and in combination with BCG showed that immunization with Mtb-HAg alone induced a significantly higher specific immune response than with BCG and significantly stimulated lymphocyte proliferation. Immunization with Mtb-HAg in combination with BCG induced a stronger specific Th1 immune response, thereby significantly improving the immunogenicity of BCG, and demonstrating the potential of Mtb-HAg as a candidate subunit vaccine.

The application discloses a Rhododendron molle flower extract with immunosuppressive activity and a preparation method and application thereof. The Rhododendron molle flower extract is prepared by taking dried flower powder of Rhododendron molle as raw material and 95% ethanol as an extracting agent under the following conditions: condensation reflux extraction for 2 hours at 60 DEG C and a material-liquid ratio of 1:10. The extract is filtered and collected, and the above extract is combined and concentrated under vacuum and reduced pressure to obtain the Rhododendron molle flower extract. The extract has an inhibitory rate of 61.41% on T lymphocyte proliferation induced by abrin and an inhibitory rate of 51.54% on B lymphocyte proliferation induced by lipopolysaccharide at a concentration of 100 mg / mL, and has no cytotoxicity on normal mouse spleen lymphocytes. The application provides a candidate research material for researching and developing a new immunosuppressant, and provides a scientific basis for developing and utilizing the Rhododendron molle resources.

This invention provides a plant-based composition comprising a first component, a second component, and a third component. The first component comprises 1-3 parts by weight of protein melanin and 1-3 parts by weight of phenylethanoid glycoside. The second component comprises 10-14 parts by weight of Polygonatum sibiricum powder, 8-12 parts by weight of licorice powder, 8-12 parts by weight of wolfberry powder, 8-14 parts by weight of longan powder, 8-16 parts by weight of jujube powder, 12-15 parts by weight of Poria cocos powder, and 7-10 parts by weight of red rose powder. The third component comprises 3-5 parts by weight of γ-aminobutyric acid (GABA), 2-6 parts by weight of erythritol, 3-5 parts by weight of citric acid, 2-4 parts by weight of sucralose, and 3-5 parts by weight of ascorbic acid. This invention uses protein melanin and phenylethanoid glycoside as the main active ingredients, supplemented with Polygonatum sibiricum powder, Poria cocos powder, and GABA. Experiments have shown that this composition can prolong the swimming time of mice under load and improve their lymphocyte proliferation capacity. This composition can regulate bodily functions and enhance immunity.

Provided in the present application is an anti-Siglec 15 antibody or an antigen-binding fragment thereof, a pharmaceutical composition and immunoconjugate comprising the antibody or antigen-binding fragment, a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell comprising the vector, a method for preparing the antibody or antigen-binding fragment, and the biological medical use of the antibody or antigen-binding fragment. The use comprises regulating the immune response, reversing the inhibition of the Siglec15 protein on PBMC lymphocyte proliferation or treating tumors associated with abnormal Siglec 15 expression.

The present invention belongs to the field of vaccine technology, and specifically relates to a self-assembled ferritin nanoparticle recombinant protein SFT, a preparation method thereof, and an application thereof. The recombinant protein SFT is self-assembled from the SpyCatcher003-Fer protein and the SpyTag003-TB10.4 protein. The tuberculosis vaccine prepared using the self-assembled ferritin nanoparticle recombinant protein SFT of the present invention, compared with monomeric TB10.4, significantly increased the level of lymphocyte proliferation after subcutaneous immunization with SFT without the aid of an adjuvant, and has the ability to induce T cell activation and can stimulate a variety of TB-related cytokines. These results show that SFT is significantly superior to traditional recombinant proteins and vaccines, which helps to broaden the types of new tuberculosis candidate vaccines and provide a nanoparticle capture platform for other tuberculosis antigens in the future.

The invention discloses a brucella-tubercle bacillus bigeminy recombinant vaccine based on an outer membrane protein OMP31 and application of the brucella-tubercle bacillus bigeminy recombinant vaccine, and belongs to the technical field of biological medicines. The invention aims at developing a brucella-tubercle bacillus bivalent vaccine, based on a brucella OMP31 gene and a tuberculosis vaccine strain bacillus calmette guerin (rBCG) vector, gene recombination is carried out, a recombinant vector is constructed, and the immune protection effect of mice is verified. According to the invention, the recombinant BCG vaccine rBCG-OMP31 is successfully constructed, and the recombinant BCG strain grows well; after a mouse is immunized, T lymphocyte proliferation is promoted, an immune state dominated by Th1 type immune response is formed, and the immune protection effect of the mouse can be remarkably improved. Therefore, data support is provided for developing safe and effective Brucella BCG vector candidate vaccines.

A method for increasing dendritic cell migration ability, and a use thereof are disclosed. A method according to one aspect can increase the migration ability of mature dendritic cells and increase the induction, by dendritic cells, of inflammatory cytokine production, T lymphocyte proliferation and T lymphocyte polarization, and thus can be used for the prevention or treatment of immune-related diseases.

The invention relates to a method for assessing the efficacy of an immunotherapy comprising administration of GAD to a patient, comprising the following steps: measuring at least one of GADA IgG subclass distribution; GADA levels; distribution of cytokines secreted from lymphocytes; and lymphocyte proliferation in presence of GAD or CD3 / CD28 beads; in a first blood, plasma or serum sample obtained from said patient at a first point in time and in a second blood, plasma or serum sample obtained from said patient at a later point in time; and comparing the so obtained measurements. The invention also relates to novel administration regimens of GAD in treatment or prevention of type 1 diabetes, that may include administration by injection into a lymph node, oral administration of vitamin D and / or an assessment of efficacy according to the above methodology followed by an adjustment of dosage and / or administration route based on said assessment.

The invention discloses a miRNA simulant for inhibiting expression of a large yellow croaker SOCS1 gene and application of the miRNA simulant, and belongs to the field of molecular biotechnology and gene engineering. The miRNA simulant is miR-7132a, and the nucleotide sequence of the miRNA simulant is shown as SEQ ID NO. 2. The invention discloses a miR-7132a simulant which is synthesized by a sense strand and an antisense strand, and the nucleotide sequence of the miR-7132a simulant is shown as SEQ ID NO.3-SEQ ID NO.4. When the miR-7132a simulant is transfected in primary head kidney lymphocytes of large yellow croakers, the mRNA level of SOCS1 genes of the large yellow croakers can be remarkably reduced, and T and B lymphocyte proliferation can be promoted, so that adaptive immune response is enhanced. Therefore, the miR-7132a simulant has a potential application value in development of the pseudosciaena crocea immunomodulator.